Publication date: Jun 24, 2025
This first-in-human positron emission tomography (PET) study evaluates [F]OXD-2314, a radiopharmaceutical designed for imaging tau in non-Alzheimer’s disease tauopathies. Synthesis of [F]OXD-2314 was automated using a commercial module and validated for human use. Dynamic PET imaging was performed in healthy control subjects (2 female, 2 male, ages 49-65 years). Kinetic modelling was performed from brain time-activity curves and radiometabolite-corrected arterial input functions to estimate total distribution volumes (V) in each region of interest. [F]OXD-2314 met all release criteria for human use. PET imaging revealed an initial whole brain peak of 2. 3 standardized uptake value, followed by a steady washout. Distribution of radioactivity was uniform among brain regions (V range: 2. 21 +/- 0. 29 to 2. 81 +/- 0. 43 mL/cm). [F]OXD-2314 was successfully translated to first-in-human PET imaging. No adverse events were reported and PET imaging in patient populations of non-AD tauopathies is underway.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Alzheimer | [18F]OXD-2314 |
| Female | Alzheimer’s disease |
| Radiometabolite | First-in-human |
| Tomography | PET |
| Tau |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Alzheimer’s disease |
| disease | MESH | tauopathies |
| drug | DRUGBANK | Methionine |
| pathway | REACTOME | Release |
| disease | MESH | neurodegenerative diseases |
| pathway | REACTOME | Neurodegenerative Diseases |
| disease | MESH | palsy |
| disease | MESH | corticobasal degeneration |
| drug | DRUGBANK | Cannabidiol |
| drug | DRUGBANK | Phenindione |
| drug | DRUGBANK | Spinosad |
| drug | DRUGBANK | Safrazine |
| disease | MESH | sterility |
| drug | DRUGBANK | L-Valine |
| drug | DRUGBANK | Ademetionine |